Systems Biology of Vaccination for EV71 Vaccine in Humans

Systems Biology of Vaccination for EV71 Vaccine in Chinese Healthy Children Aged From 2 to 5 Years Old

Recently, an inactivated vaccine (vero cell) against EV71 has been investigated in Phase 1 and Phase 2 clinical trials. Data from these trials showed that the EV71 vaccine has good safety profile and was immunogenic. 320 U alum-adjuvant vaccine has been chosen as the candidate vaccine for the phase 3 clinical trial.

This clinical trial is a supplementary phase 2 trial, which is designed to study the gene expression patterns induced by EV71 vaccine in Chinese healthy children aged from 2 to 5 years old use a systems biology approach combined with microarray analysis，RT-PCR and neutralizing antibody testing for PBMC and serum collected form the studied children population, to predict immunogenicity, and explore mechanistic insights about the EV71 vaccine.

Study Overview

• Status: Completed
• Conditions: Systems Biology; Early Gene; EV71 Vaccine
• Intervention / Treatment: Biological: 320U /0.5ml; Biological: 0/0.5ml placebo

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Phase 2

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210009
      • Jiangsu Provincial Center for Diseases Control and Prevention

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years to 5 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy subjects aged from 2 to 5 years old as established by medical history and clinical examination
• The pre-vaccination neutralizing antibody against EV71 <1:8 which is determined by ELISA
• The subjects' guardians are able to understand and sign the informed consent
• Had never received the vaccine against EV71
• Subjects who can and will comply with the requirements of the protocol
• Subjects with temperature <37.1°C on axillary setting

Exclusion Criteria:

• Subject who has a medical history of HFMD
• <= 37 weeks gestation
• Subjects with a birth weight <2.5 kg
• Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
• Family history of seizures or progressive neurological disease
• Family history of congenital or hereditary immunodeficiency
• Severe malnutrition or dysgenopathy
• Major congenital defects or serious chronic illness, including perinatal brain damage
• Autoimmune disease
• Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws
• Any acute infections in last 7 days
• Any prior administration of immunodepressant or corticosteroids in last 6month
• Any prior administration of blood products in last 3 month
• Any prior administration of other research medicines in last 1month
• Any prior administration of attenuated live vaccine in last 28 days
• Any prior administration of inactivated vaccines in last 14 days, such as pneumococcal vaccine
• Under the anti - TB prevention or therapy
• Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 320U /0.5ml in children (from 2 to 5 years old); inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28	Biological: 320U /0.5ml; inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
Placebo Comparator: 0/0.5ml placebo in children (from 2 to 5 years old); 0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28	Biological: 0/0.5ml placebo; 0/0.5ml placebo, two doses, 4 weeks interval

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine	Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 3 in children aged 2-5 years	Frame: 3 days after first dose
Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine	Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 7 in children aged 2-5 years	7 days after first dose
Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine	Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 28 in children aged 2-5 years	28 days after first dose
Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine	Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 56 in children aged 2-5 years	28 days after second dose
Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine	Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at month 6 in children aged 2-5 years	6 months after first dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
GMT, seroconversion rate of anti-EV71 antibodies in serum after first vaccination	GMT, seroconversion rate of anti-EV71 antibodies in serum 28 days after first vaccination	28 days after the first vaccination
GMT, seroconversion rate of anti-EV71 antibodies in serum after second vaccination	GMT, seroconversion rate of anti-EV71 antibodies in serum 28 days after second vaccination	28 days after second vaccination
the safety of EV71 vaccine in healthy children aged 2-5 years	Frequency of systemic and local adverse reactions within 28 days after the first dose of EV71 vaccine in healthy children aged 2-5 years	28 days after the first dose
the safety of EV71 vaccine in healthy children aged 2-5 years	Frequency of systemic and local adverse reactions within 28 days after the second dose of EV71 vaccine in healthy children aged 2-5 years	28 days after the second dose

Collaborators and Investigators

• Sponsor: Jiangsu Province Centers for Disease Control and Prevention
• Collaborators: Bejing Vigoo Biological Co., LTD

Study record dates

Study Major Dates

• Study Start: August 1, 2012
• Primary Completion (Actual): May 1, 2013
• Study Completion (Actual): May 1, 2013

Study Registration Dates

• First Submitted: September 1, 2012
• First Submitted That Met QC Criteria: September 1, 2012
• First Posted (Estimate): September 6, 2012

Study Record Updates

• Last Update Posted (Estimate): May 8, 2013
• Last Update Submitted That Met QC Criteria: May 7, 2013
• Last Verified: May 1, 2013

More Information

Terms related to this study

• Other Study ID Numbers: JSVCT012